Back to search results

Misoprostol for Fluid Deficit in Hysteroscopic Myomectomy

This study is looking at whether misoprostol (a medication often used in gynecology) can help reduce fluid loss during a hysteroscopic myomectomy (a procedure to remove fibroids from the uterus). You could be eligible if you are a woman between 18 and 50 years old, have uterine fibroids between 1-3cm, and are scheduled for a hysteroscopic myomectomy. Participants will either receive 800 mcg of misoprostol or a placebo (an inactive substance called Zeebo) rectally before their procedure. The main goal is to see if there's a difference in the amount of fluid lost immediately after the procedure between those who received misoprostol and those who received the placebo. The study's current status is unclear.

Study design
This is a double-blinded randomized controlled trial, meaning neither you nor your doctors will know if you are receiving misoprostol or a placebo. It plans to enroll 40 participants.
What's involved
You would need to be willing to have misoprostol or placebo given rectally at the time of your hysteroscopic myomectomy procedure.
Compensation
Not stated in the trial record.
Follow-up
Fluid deficit will be measured immediately at the conclusion of the procedure.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07286188

Effect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy

Recruiting
PHASE4Ages 18–50InterventionalTreatment
Northwestern University
~40 participants
Updated 2026-06-01 on ClinicalTrials.gov
What's tested:Misoprostol TabetsPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Fluid Deficit
Measured over Immediately at the conclusion of the procedure.

Conditions

Fibroids, Uterine
Fluid Deficit
Hysteroscopy / Methods

Explore related trials

Uterine Corpus Leiomyoma

NCT07286188

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Northwestern

    Chicago, Illinoisstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Magy Milad, MD · PRINCIPAL_INVESTIGATOR · Northwestern University Feinberg School of Medicine, Northwestern Department of Obstetrics and Gynecology, Division of Minimally Invasive Gyn Surgery

Who to contact

Hannah Pope, MD
[email protected]
3126946773
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients presenting for hysteroscopic myomectomy for uterine fibroids on pelvic imaging (pelvic ultrasound or MRI) within in last 12 months
Age ≥ 18 years and ≤ 50 years.
Fibroids between 1-3cm in size
Myomectomy using myosure or resectoscope devices
Willing to have rectal misoprostol or placebo at time of procedure
Ability to understand and the willingness to sign a written informed consent.
Admissible medical/surgical history.
Can be previously treated with Depo-Lupron, Depo-Provera, or Oral Contraceptive pills
Can have had prior Cesarean delivery

Exclusion

Pregnancy. All patients will be required to have a negative urine pregnancy test prior to surgery.
Post-menopausal women.
Patients with a history of gynecologic malignancy.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to misoprostol.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Known active inflammatory bowel disease involving the rectum or other significant anorectal conditions that may interfere with safe rectal administration of study medication.

What this trial measures

  • Fluid DeficitImmediately at the conclusion of the procedure.

    Primary outcome is difference in fluid deficit at the conclusion of the hysteroscopic myomectomy